Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy

NCT07073755 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT07073755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07073755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy
Lead sponsor
Hunan Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2023
Completion date
June 1, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug resistance, her2-positive breast cancer, hormone receptor-positive breast cancer, metastatic breast cancer, treatment decisions, triple-negative breast cancer (tnbc)